The role of carfilzomib in relapsed/refractory multiple myeloma

被引：15
|
作者：
Yee, Andrew J. [1 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Ctr Multiple Myeloma, 55 Fruit St, Boston, MA 02114 USA
来源：
THERAPEUTIC ADVANCES IN HEMATOLOGY | 2021年 / 12卷
关键词：
carfilzomib; multiple myeloma; PROTEASOME INHIBITOR CARFILZOMIB; ONCE-WEEKLY CARFILZOMIB; LOW-DOSE DEXAMETHASONE; RANDOMIZED PHASE-III; SINGLE-AGENT; IRREVERSIBLE INHIBITOR; SURVIVAL ANALYSIS; SAFETY PROFILE; OPEN-LABEL; BORTEZOMIB;
D O I：
10.1177/20406207211019612
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and as a partner in diverse three drug combinations such as with lenalidomide or daratumumab. While it has an established place in relapsed disease, clinicians should be aware of its cardiovascular and renal adverse event profile, which is manageable, in order to optimize outcomes. This review will provide a perspective on the current and future role of carfilzomib in relapsed/refractory multiple myeloma.
引用
收藏
页数：13
相关论文
共 50 条
  • [1] Carfilzomib In Relapsed, or Relapsed and Refractory, Multiple Myeloma
    McCormack, Paul L.
    DRUGS, 2012, 72 (15) : 2023 - 2032
  • [2] Carfilzomib for relapsed and refractory multiple myeloma
    Groen, K.
    van de Donk, N. W. C. J.
    Stege, C. A. M.
    Zweegman, S.
    Nijhof, I. S.
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 2663 - 2675
  • [3] Carfilzomib for relapsed or refractory multiple myeloma
    Tanimoto, Tetsuya
    Tsuda, Kenji
    Oshima, Kumi
    Mori, Jinichi
    Shimmura, Hiroaki
    LANCET ONCOLOGY, 2018, 19 (01): : E1 - E1
  • [4] Carfilzomib for relapsed or refractory multiple myeloma reply
    Dimopoulos, Meletios A.
    Kimball, Amy S.
    LANCET ONCOLOGY, 2018, 19 (01): : E2 - E2
  • [5] A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma
    Franken, B.
    van de Donk, N. W. C. J.
    Cloos, J. C.
    Zweegman, S.
    Lokhorst, H. M.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (06) : 330 - 344
  • [6] Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
    Fostier, Karel
    De Becker, Ann
    Schots, Rik
    ONCOTARGETS AND THERAPY, 2012, 5 : 237 - 244
  • [7] Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma
    Boccon-Gibod, Clementine
    Talbot, Alexis
    Le Bras, Fabien
    Frenzel, Laurent
    Royer, Bruno
    Harel, Stephanie
    Lombion, Naelle
    Belhadj, Karim
    Cuccuini, Wendy
    Arnulf, Bertrand
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (03) : E73 - E76
  • [8] Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
    Stewart, A. Keith
    FUTURE ONCOLOGY, 2015, 11 (15) : 2121 - 2136
  • [9] Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
    Jain, Salvia
    Diefenbach, Catherine
    Zain, Jasmine
    O'Connor, Owen A.
    CORE EVIDENCE, 2011, 6 : 43 - 57
  • [10] Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
    Nooka, Ajay
    Gleason, Charise
    Casbourne, Daniela
    Lonial, Sagar
    BIOLOGICS-TARGETS & THERAPY, 2013, 7 : 13 - 32
12345